Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Not Confirmed
Not Confirmed
12-14 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Tides Asia
Not Confirmed
Contact SupplierTides Asia
Industry Trade Show
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Industry Trade Show
Not Confirmed
12-14 January, 2026
Digital content
NEWS #PharmaBuzz
17 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/17/3206854/0/en/EyePoint-to-Present-at-the-44th-Annual-J-P-Morgan-Healthcare-Conference.html
16 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/16/3206087/0/en/EyePoint-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html
19 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/19/3190786/0/en/EyePoint-Announces-Positive-Recommendation-from-Independent-Data-Safety-Monitoring-Committee-for-Pivotal-Phase-3-Trials-for-DURAVYU-in-Wet-Age-Related-Macular-Degeneration.html
17 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/17/3188984/0/en/EyePoint-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html
05 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/05/3181259/0/en/EyePoint-Reports-Third-Quarter-2025-Financial-Results-and-Highlights-Recent-Corporate-Developments.html
29 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/29/3176260/0/en/EyePoint-to-Report-Third-Quarter-2025-Financial-Results-on-November-5-2025.html
Drugs in Development
Details:
The proceeds from the offering will be used to fund the clinical development of Vorolanib, targeting angiogenesis inhibitors for wet age-related macular degeneration.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Brand Name: Duravyu
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: J.P. Morgan
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 14, 2025
Lead Product(s) : Vorolanib
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $150.0 million
Deal Type : Public Offering
Eyepoint Plans Public Offering of Common Stock
Details : The proceeds from the offering will be used to fund the clinical development of Vorolanib, targeting angiogenesis inhibitors for wet age-related macular degeneration.
Product Name : Duravyu
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 14, 2025
Details:
The proceeds from the offering will be used to fund the clinical development of Vorolanib, targeting angiogenesis inhibitors for wet age-related macular degeneration.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Brand Name: Duravyu
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: J.P. Morgan
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 14, 2025
Lead Product(s) : Vorolanib
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $150.0 million
Deal Type : Public Offering
Eyepoint Sets Price for Public Offering
Details : The proceeds from the offering will be used to fund the clinical development of Vorolanib, targeting angiogenesis inhibitors for wet age-related macular degeneration.
Product Name : Duravyu
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 14, 2025
Details:
Duravyu delivers vorolanib, a selective TKI formulated in a solid bioerodible insert. It is under clinical development for the treatment of diabetic macular edema.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Brand Name: Duravyu
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 05, 2025
Lead Product(s) : Vorolanib
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
EyePoint’s DURAVYU™ Hits Phase 2 VERONA Trial Goals in Diabetic Macular Edema
Details : Duravyu delivers vorolanib, a selective TKI formulated in a solid bioerodible insert. It is under clinical development for the treatment of diabetic macular edema.
Product Name : Duravyu
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 05, 2025
Details:
Duravyu delivers vorolanib, a selective TKI formulated in a solid bioerodible insert. It is under clinical development for the treatment of Wet-AMD.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Brand Name: Duravyu
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 04, 2024
Lead Product(s) : Vorolanib
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
EyePoint Begins Phase 3 LUCIA Trial Of DURAVYU™ in Wet AMD
Details : Duravyu delivers vorolanib, a selective TKI formulated in a solid bioerodible insert. It is under clinical development for the treatment of Wet-AMD.
Product Name : Duravyu
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 04, 2024
Details:
EYP-1901 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Wet Macular Degeneration.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 12, 2024
Lead Product(s) : Vorolanib
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EYP-1901 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Wet Macular Degeneration.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 12, 2024
Details:
EYP-1901 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Wet Macular Degeneration.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 31, 2024
Lead Product(s) : Vorolanib
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EYP-1901 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Wet Macular Degeneration.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 31, 2024
Details:
The intends to use the net proceeds from the offering to advance clinical development of Duravyu (Vorolanib) for wet age related macular degeneration (wet AMD) and diabetic macular edema.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: J.P. Morgan
Deal Size: $161.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 31, 2024
Lead Product(s) : Vorolanib
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $161.0 million
Deal Type : Public Offering
EyePoint Closes Upsized Offering And Option for Additional Shares
Details : The intends to use the net proceeds from the offering to advance clinical development of Duravyu (Vorolanib) for wet age related macular degeneration (wet AMD) and diabetic macular edema.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 31, 2024
Details:
The intends to use the net proceeds from the offering to advance clinical development of Duravyu (Vorolanib) for wet age related macular degeneration (wet AMD) and diabetic macular edema.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: J.P. Morgan
Deal Size: $140.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 29, 2024
Lead Product(s) : Vorolanib
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $140.0 million
Deal Type : Public Offering
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering
Details : The intends to use the net proceeds from the offering to advance clinical development of Duravyu (Vorolanib) for wet age related macular degeneration (wet AMD) and diabetic macular edema.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 29, 2024
Details:
Duravyu (vorolanib) is a selective TK inhibitor formulated in a solid bioerodible insert using Durasert E technology. It is under phase 2 clinical development for the treatment ofD ME.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 29, 2024
Lead Product(s) : Vorolanib
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
EyePoint's Duravyu Bounces Back with Promising DME Data
Details : Duravyu (vorolanib) is a selective TK inhibitor formulated in a solid bioerodible insert using Durasert E technology. It is under phase 2 clinical development for the treatment ofD ME.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 29, 2024
Details:
The intends to use the net proceeds from the offering to advance clinical development of Duravyu (Vorolanib) for wet age related macular degeneration (wet AMD) and diabetic macular edema.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: J.P. Morgan
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering October 28, 2024
Lead Product(s) : Vorolanib
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : Undisclosed
Deal Type : Public Offering
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
Details : The intends to use the net proceeds from the offering to advance clinical development of Duravyu (Vorolanib) for wet age related macular degeneration (wet AMD) and diabetic macular edema.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 28, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
Share 
